oronary interventions on small vessels, representing up to 30% to 40% of procedures, are challenging and often disappointing because of suboptimal acute results and high restenosis rates (1,2). In this setting, bare-metal stents (BMS) proved to be superior to balloon angioplasty (BA), with the greatest benefit encountered in patients with smaller vessels and suboptimal BA results (1,2). outcomes were also improved after SES implantation, driven by a significant reduction in the need for target lesion revascularization. Finally, regarding myocardial infarction, DCB were ranked first, followed by
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Because late luminal loss resulting from neointimal proliferation is relatively independent of vessel size, late angiographic findings after BMS implantation are poorer in small vessels (1, 2) . Drug-eluting stents (DES) drastically inhibit neointimal proliferation and are especially attractive in these patients. However, even with the advent of new-generation DES, small vessel disease remains a powerful predictor of restenosis (3). More recently, drug-coated balloons (DCB) have been incorporated into our armamentarium for lesions in small vessels, with promising results (4, 5) . have reported that they have no relationships relevant to the contents of this paper to disclose. E-mail: falf@hotmail.com.
